NCT04821687View on ClinicalTrials.gov

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

PHASE4CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
Parkinson Disease
Interventions
DRUG

Ongentys 50mg

Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI

DRUG

Madopar Tab. 125 or Perkin Tab. 25-100mg

Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI

Trial Locations (1)

Unknown

Hallym University Sacred Heart Hospital, Anyang-si

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY